Two kinds of hypoglycemic drugs are very effective in colorectal cancer

Obesity is on the rise worldwide and is related to the incidence of colon cancer , but its mechanism has been a mystery. In a new study, Yale University research discovered how obesity drives tumor growth in mice and revealed potential strategies to combat this cancer pathogenesis.

The team studied mice implanted with genetic models of tumors or colon cancer. The researchers first studied the effect of a high-fat diet on mice. Then they gave the mice one of two drugs: one was the controlled release mitochondrial proton mass (CRMP), and the other was metformin (the world’s most commonly used diabetes prescription drug), which burns fat in the liver drug.

The team found that high levels of insulin are the link between obesity and colon cancer. Insulin increases glucose uptake in tumors and  promotes tumor growth. The  researchers also found that both drugs can reduce insulin levels and slow tumor growth in mice.

The researchers say that this study is the first to demonstrate that obesity-induced high insulin levels drive colon cancer by increasing glucose uptake in these models. Although further research is needed to confirm whether these findings are applicable to humans, insulin reduction therapy: metformin, CRMP , And even exercise can help slow or prevent colon cancer.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer
• Susan Hau

  https://cancerfax.com/author/susan/

  PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy
• Susan Hau

  https://cancerfax.com/author/susan/

  Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma
• Susan Hau

  https://cancerfax.com/author/susan/

  Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

• Comments Closed
• May 12th, 2020